Analyst Price Targets — ALX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 21, 2026 10:56 am | Alexander Goldfarb | Piper Sandler | $212.00 | $281.51 | TheFly | Alexander's price target raised to $212 from $190 at Piper Sandler |
| August 6, 2024 7:29 am | Alexander Goldfarb | Piper Sandler | $125.00 | $217.11 | StreetInsider | Alexander's (ALX) PT Lowered to $125 at Piper Sandler |
| May 13, 2024 10:14 am | Alexander Goldfarb | Piper Sandler | $145.00 | $216.71 | StreetInsider | Alexander's (ALX) PT Lowered to $145 at Piper Sandler |
Latest News for ALX
Here is how Alexander's (ALX) and Healthpeak (DOC) have performed compared to their sector so far this year.
DINO, QUAD and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 11, 2026.
ALX, DINO, OPBK, CYD and HLLY have been added to the Zacks Rank #1 (Strong Buy) List on August 11, 2026.
ALX, SHIP and QUAD made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 11, 2026.
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALX.
U.S. House Trading
No House trades found for ALX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.